Understanding PDCD
What is PDCD?
Pyruvate Dehydrogenase Complex Deficiency (PDCD) is a rare genetic metabolic disorder affecting about 1 in 40,000 children. In simple terms, it affects the body’s ability to turn food into usable energy – specifically, the ability to convert glucose into fuel for cells. Because nearly every part of the body depends on that energy, PDCD can affect the brain, muscles, and other organs, often all at once.
No two cases look the same
PDCD doesn’t follow one script. Some children are diagnosed shortly after birth with severe, life-threatening symptoms. Others have a milder course and aren’t diagnosed until later in childhood. Common features include:
- Developmental delays
- Seizures
- Muscle weakness and low muscle tone (hypotonia)
- Movement disorders
- Structural brain differences
- Episodes of metabolic crisis, often triggered by illness or stress
Because the presentation varies so widely, families often have a long and exhausting road to diagnosis. It’s common to bounce between specialists before anyone can put a name to what they are seeing. Even after diagnosis, day-to-day life with PDCD brings challenges that aren’t always visible from the outside: careful diet management, therapies, medical appointments, and the constant awareness that common childhood illnesses could turn serious quickly.
A serious, and often life-threatening, condition
It’s important to be direct about this: PDCD can be fatal, particularly in early childhood.
- In a study of 294 individuals with documented outcomes, 36.2% had died at the time of reporting. Among those, the average age at death was approximately 2.7 years.
- In a separate study of 59 symptomatic individuals with genetically confirmed PDCD, 39% had died, and 91% of those deaths occurred before age 4.
These numbers are sobering, and they’re why early recognition and research matter so much. PDCD spans a real spectrum. Some children with milder forms live into adolescence and adulthood, and outcomes continue to improve as research progresses and understanding of the condition grows.
Why this matters
PDCD is rare enough that most people, including many medical professionals, have never encountered it. That unfamiliarity has real consequences: delayed diagnoses, families who feel like they’re explaining their child’s condition from scratch every time, and a research base that’s still catching up.
Every mile run, walked, or logged for this cause helps change that by funding research, supporting families, and putting a rare disease in front of people who might otherwise never hear its name.
Hope for PDCD
Miles for PDCD is proud to support the work of Hope for PDCD, a family-led organization dedicated to supporting individuals and families affected by PDCD while advancing awareness, education, and research.
Progress and momentum
Research into PDCD has accelerated in recent years, and families have real reasons for hope.
The ketogenic diet. For decades, a carefully managed medical ketogenic diet has been one of the few tools available for PDCD. It shifts the body’s fuel source from glucose to fats and ketones, bypassing the very step that PDCD disrupts. It’s not a cure, but the evidence behind it keeps growing.
A potential first-ever approved treatment. For decades, there has been no FDA-approved therapy for PDCD at all. That may be about to change. Sodium dichloroacetate (DCA), a drug studied since the 1980s, has gone through a pivotal Phase 3 trial, and its manufacturer has resubmitted its New Drug Application to the FDA in the summer of 2026. The FDA has accepted the resubmission and set a target action date of December 30, 2026. If approved, it would be the first drug ever specifically approved for PDCD.
Gene therapy research at UT Southwestern. Beyond diet and drug therapies, Hope for PDCD is funding early-stage gene therapy research through the Gray Lab at UT Southwestern Medical Center. This research uses a virus (AAV) to deliver a working copy of a gene directly into cells. The Gray Lab has completed a proof-of-concept study in mouse models of PDCD, a foundational step toward one day testing gene therapy in human clinical trials. This kind of research is exactly what a surge in funding can accelerate – moving a promising approach from the lab bench closer to patients. Hope for PDCD has called gene therapy the best current hope for a true cure for PDCD.
Growing research base. Beyond DCA, researchers are actively working on newborn screening for PDCD (so families could get answers far earlier than the diagnostic journey many face today), natural history studies to better understand how the disease progresses, and other important research. Each study adds to scientific knowledge of PDCD and builds momentum.
None of this happens without visibility and funding, which is exactly what Miles for PDCD exists to help drive!